Navigation Links
Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine
Date:9/19/2013

NEW YORK, September 19, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Pfizer Inc. (NYSE: PFE), GlaxoSmithKline plc (NYSE: GSK), Sanofi SA (NYSE: SNY), AstraZeneca PLC (NYSE: AZN), and Neurocrine Biosciences, Inc. (NASDAQ: NBIX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

On September 12, 2013, ViiV Healthcare, a joint company by Pfizer Inc. (Pfizer) and GlaxoSmithKline plc (GlaxoSmithKline), announced initial results from the Phase IIIb/IV FLAMINGO (ING114915) study. The Company noted that the open-label study compared once-daily regimens containing 50mg dolutegravir with once-daily regimens containing a protease inhibitor (PI) (800mg darunavir boosted with 100mg ritonavir) in treatment-naive adults with HIV-1. At the 48-week time point between the dolutegravir and darunavir-based regimens, the initial results demonstrated non-inferiority. "This is the first study in our clinical programme to compare dolutegravir to a boosted protease inhibitor in treatment-naive patients. PIs are often selected as part of a first-line regimen for treatment-naive patients, so these data provide important information regarding dolutegravir as a treatment choice for these patients," said Dr. John Pottage, Chief Medical Officer of ViiV Healthcare. The Full Research Report on Pfizer Inc. - including full detailed breakdown,
'/>"/>

SOURCE Investors' Reports
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
2. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
3. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
4. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
5. Southern Research Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings
6. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
7. New Clinical Endocrinology Guidelines Support Lp-PLA2 Measurement For Risk Assessment of Coronary Artery Disease
8. First Patient Treated in U.S. Clinical Study of Cohera Medicals TissuGlu® Surgical Adhesive
9. Michael J. Fox Foundation-Funded Study Identifies Best Dyskinesia Clinical Rating Scale
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... -- Research and Markets ( ... "Craniomaxillofacial Implants Market - Global Industry Analysis, ... 2022" report to their offering. ... the current and future prospects of the global ... the global market due to increasing facial deformities ...
(Date:7/28/2015)...  SeraCare Life Sciences, a leading partner to ... the American Association of Clinical Chemistry (AACC) meeting ... the University of California, San Francisco (UCSF) for ... (T18) and Trisomy 13 (T13) trophoblast cell line ... materials for Non-Invasive Prenatal Testing (NIPT) of chromosomal ...
(Date:7/28/2015)... , July 28, 2015  PD-Rx Pharmaceuticals, ... announced that it has partnered with Dobson Technologies, ... as a Service (IaaS) product. PD-Rx ... practices across the United States.  Using Dobson Technologies, ... recovery and business continuity, ensure regulatory compliance, and ...
Breaking Medicine Technology:Global Craniomaxillofacial Implants (Plate and Screw Fixator Systems, Bone Graft Substitutes, Distraction Systems, and TMJ Replacement Devices) Market Analysis 2014-2022 2SeraCare Life Sciences Signs License Agreement with UCSF and Announces Early Access Program for Development of Aneuploidy Reference Materials 2SeraCare Life Sciences Signs License Agreement with UCSF and Announces Early Access Program for Development of Aneuploidy Reference Materials 3PD-Rx Partners With Dobson Technologies 2
... Cell Therapy, Inc. ("Pathfinder")(OTCQB: PFND), a biotechnology company focused ... damage, today announced that effective at the start of ... will change from SYMD to PFND.  The new ticker ... and has been approved by the Financial Industry Regulatory ...
... 2011 Cempra Pharmaceuticals today announced abstracts to ... novel fluoroketolide antibiotic, solithromycin (CEM-101), at the ... (ICAAC) , September 17 to 20, 2011, in ... the safety and routes of administration of CEM-101, ...
Cached Medicine Technology:Pathfinder Cell Therapy, Inc. Announces New Stock Ticker Symbol 2Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 3Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 4Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 5
(Date:7/28/2015)... ... 2015 , ... By 2016, the number of smartphones worldwide will surpass 2 ... a highly personal basis, increasing customer loyalty. However, capitalizing on this is not always ... customers to more nimble competitors. , The Open Mobile Summit 2015 is an influential ...
(Date:7/28/2015)... ... July 28, 2015 , ... Morristown Medical Center, part of ... one of the first five hospitals in the nation, to implant the newly approved ... July 23, and all are in good condition. , The CoreValve® Evolut® R System ...
(Date:7/28/2015)... ... July 28, 2015 , ... Dr. Edward Buckingham ... of Dr. Sudeep Roy in July 2016. Coming to Austin from Philadelphia, Dr. ... Buckingham. The twelve-month long training is facilitated annually by the American Academy of ...
(Date:7/28/2015)... ... July 28, 2015 , ... Autism is ... 68 children currently affected with the disorder. For these families, identifying and paying ... recovery is extremely daunting. That’s where Talk About Curing Autism (TACA), a national ...
(Date:7/28/2015)... ... 2015 , ... Representatives with CareMed Urgent & Primary Care ... National Immunization Awareness Month, which is the month of August. , “Immunization helps ... the flu, measles, and pneumonia, adults need to get their shots – just ...
Breaking Medicine News(10 mins):Health News:Open Mobile Media: Etsy, Google, The Weather Company, CBS, TaskRabbit and New York Times: Moving from Web to Mobile-First 2Health News:Open Mobile Media: Etsy, Google, The Weather Company, CBS, TaskRabbit and New York Times: Moving from Web to Mobile-First 3Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 2Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 3Health News:Buckingham Center for Facial Plastic Surgery Welcomes Fellow 2Health News:Buckingham Center for Facial Plastic Surgery Welcomes Fellow 3Health News:National TACA Autism Conference Offers Hope and Help to Families Affected by Autism 2Health News:CareMed Urgent & Primary Care Supports National Immunization Awareness Month 2Health News:CareMed Urgent & Primary Care Supports National Immunization Awareness Month 3
... supports the theory that bringing about senescence in aged ... ,Inducing senescence in aged cells may be sufficient to ... published online this week in European Molecular Biology Organization ... or programmed cell death – apoptosis – was the ...
... be sufficient to guard against spontaneous cancer development, ... in EMBO reports//. It was previously unknown whether ... – was the more important safeguard mechanism for ... cells have abnormal chromosomes with dysfunctional telomeres – ...
... dead due to the infection of a hospital superbug at ... Clostridium Difficile, commonly known as C diff, within the last ... of the patients were infected with a virulent strain of ... had to be performed on five other patients who had ...
... much of the molecular machinery required for life, are ... all proteins are membrane proteins – embedded within the ... the other two-thirds using such tools as antibodies, they ... portions of proteins. ,To probe the secrets ...
... at the University of Alabama at Birmingham's Magnetic Source ... , using MEG (magneto-encephalography) scanners to learn more about ... types of brain scans detail the geography of the ... the magnetic signals that neurons throw off as they ...
... -- Researchers have identified the receptor pathway used by ... The related report by Hsieh et al, “G protein-coupled ... nongenomic effects of estrogen in attenuating liver injury after ... Journal of Pathology and is accompanied by a commentary. ...
Cached Medicine News:Health News:Penn Scientists Engineer Small Molecules to Probe Proteins Deep Inside Cell Membrane 2Health News:MEG Scanners Are Mega Powerful 2Health News:Estrogen Protects Liver After Traumatic Injury 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: